Cite
HARVARD Citation
Raal, F. et al. (2015). PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 385 (9965), pp. 331-340. [Online].